APA aipamena

Imamura, F., Inoue, T., Kunimasa, K., Kubota, A., Kuhara, H., Tamiya, M., . . . Kumagai, T. (2020). Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC. Lung Cancer Manag.

Chicago Style aipamena

Imamura, Fumio, et al. "Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-positive NSCLC." Lung Cancer Manag 2020.

MLA aipamena

Imamura, Fumio, et al. "Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-positive NSCLC." Lung Cancer Manag 2020.